Adaptive Biotechnologies Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $277.0M | $179.0M | $170.3M | $185.3M | $154.3M |
| Cost of revenue | $71.4M | $72.1M | $75.6M | $57.9M | $49.3M |
| Research and development | $93.8M | $103.0M | $122.1M | $141.8M | $142.3M |
| Operating income | -$57.1M | -$162.5M | -$227.0M | -$200.2M | -$209.0M |
| Interest expense | $11.8M | $11.6M | $13.8M | $4.2M | — |
| Pretax income | -$59.5M | -$159.6M | -$225.3M | -$200.4M | -$207.3M |
| Income tax expense | $0 | $0 | $0 | — | — |
| Net income | -$59.5M | -$159.5M | -$225.2M | -$200.2M | -$207.3M |
| Balance Sheet | |||||
| Cash and equivalents | $70.5M | $47.9M | $65.1M | $90.0M | $139.1M |
| Current assets | $300.2M | $283.8M | $410.2M | $562.1M | $402.7M |
| Total assets | $512.7M | $539.4M | $661.1M | $856.6M | $923.3M |
| Current liabilities | $89.9M | $98.1M | $88.0M | $109.8M | $113.8M |
| Total liabilities | $287.7M | $336.9M | $352.9M | $392.5M | $319.2M |
| Stockholders' equity | $218.8M | $202.7M | $308.4M | $464.2M | $604.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$46.0M | -$95.2M | -$156.3M | -$183.9M | -$192.7M |
| Depreciation and amortization | $16.1M | $17.6M | $20.5M | $19.2M | $12.3M |
| Stock-based compensation | $51.5M | $53.6M | $62.9M | $55.5M | $43.3M |
| Capital expenditure | $3.0M | $3.7M | $10.7M | $16.3M | $61.7M |
| Free cash flow | -$48.9M | -$98.9M | -$167.0M | -$200.3M | -$254.5M |
| Impairments | $0 | $7.2M | $0 | $0 | $0 |
Shares outstanding 160.0M · Free float 94.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.